Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies

Sezgın, Orhan; Aydın, Mehmet Kasım; Özdemir, Asena Ayça; Kanık, Arzu

doi:10.5152/tjg.2019.18693

Cited by 23 publications

(12 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sezgin et al in their meta‐analysis in Turkey found the rate of eradication with standard triple therapy for H pylori to be 60% and 57%, respectively, according to intention‐to‐treat or per‐protocol analysis. 20 . A study by Kaplan et al showed that standard triple therapy eradication rate decreased to 55.7% in Turkey 6 .…”

Section: Discussionmentioning

confidence: 99%

Efficacy of a novel sequential treatment regimen containing bismuth forHelicobacter pylorieradication in Turkish children

2020

View full text Add to dashboard Cite

Background Eradication rates of Helicobacter pylori (H pylori) with standard triple therapy are gradually decreasing all over the world, including in children, due to the development of strains resistant to antimicrobials. Sequential therapy can be used as an alternative method to increase eradication rates. Materials and Methods A total of 75 patients ≥ 8 years of age with H pylori gastritis were included in the study. According to Rome IV criteria, 38 patients had functional abdominal pain and dyspepsia, and 37 patients had alarm findings suggesting organic disease. Patients were treated with a novel sequential therapy consisting of the proton pump inhibitor (PPI)‐lansoprazole (1 mg/kg/day, maximum 30 mg daily), amoxicillin (50 mg/kg/d in two doses, maximum 2 × 1000 mg) for 7 days followed by PPI‐lansoprazole (1 mg/kg/d, maximum 30 mg daily), metronidazole (20 mg/kg/day in two doses, maximum 2 x 500 mg), tetracycline (50 mg/kg/d divided into four equal doses, maximum 4 x 500 mg), and bismuth subsalicylate (262 mg QID in patients ≤ 10 years of age, 524 mg QID in patients > 10 years of age in days 8‐14). Eradication status was evaluated by H pylori stool antigen test 8 weeks after the completion of treatment. Results The mean age of the patients was 15.1 ± 2.4 years and 51 (68%) were female. No patient discontinued therapy due to side effects. All patients had antral gastritis (76.0%) or pangastritis (24.0%). The peptic ulcer rate was 6.6%. Eradication therapy was given to all patients with or without peptic ulcer. H pylori eradication was achieved in 69 (92.0%) patients and symptoms improved in 61 of those eradicated. Conclusions As a first‐line treatment for H pylori eradication in children, administering a novel sequential therapy including bismuth for 14 days provides a high rate of eradication.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of a novel sequential treatment regimen containing bismuth forHelicobacter pylorieradication in Turkish children

2020

View full text Add to dashboard Cite

show abstract

“…As is the case throughout the world, in Turkey, the antibiotics most commonly used for the eradication of H. pylori are clarithromycin, metronidazole, levofloxacin, tetracycline, and amoxicillin [28][29][30][31]. Rifampicin is generally used for the treatment of tuberculosis, therefore, in order to prevent the development of resistance, this antibiotic is purposefully not used for the empirical treatment of H. pylori in Turkey.…”

Section: Discussionmentioning

confidence: 99%

Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Increasing treatment duration has been proposed as a means of improving eradication rates with TT but this was not borne out in a Korean trial comparing 7‐ with 14‐day regimens which reported similar poor success rates of 64% and 66%, respectively 8 . A meta‐analysis of 45 studies from Turkey was in agreement with just 60% achieving eradication with both 7‐ and 14‐day regimens 9 . In Indonesia, however, a 14‐day TT regimen was significantly more effective than a 10 day TT (87% vs 68%) 10 .…”

Section: Triple Therapymentioning

confidence: 99%

Review – Treatment of Helicobacter pylori infection 2020

et al. 2020

View full text Add to dashboard Cite

This review summarizes important studies regarding Helicobacter pylori therapy published from April 2019 to April 2020. The main themes that emerge involve studies assessing antibiotic resistance, and there is also growing momentum behind the utility of vonoprazan as an alternative to proton pump inhibitor (PPI) therapy and also bismuth‐based regimens as a first‐line regimen. Antibiotic resistance is rising wherever it is being assessed, and clarithromycin resistance in particular has reached a point where it may no longer be a viable therapy without previous testing in many regions of the world. The evidence for the efficacy of a bismuth‐based quadruple therapy as a first‐line therapy is now very clearly established, and there is substantial evidence that it is the best performing first‐line therapy. The utility of vonoprazan as an alternative to PPI therapy, especially in resistant and difficult‐to‐treat groups, has also been considered in great detail this year, and it may offer an opportunity in the near future to reduce the problem of antibiotic resistance.

show abstract

Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies

Cited by 23 publications

References 61 publications

Efficacy of a novel sequential treatment regimen containing bismuth forHelicobacter pylorieradication in Turkish children

Efficacy of a novel sequential treatment regimen containing bismuth forHelicobacter pylorieradication in Turkish children

Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing?

Review – Treatment of Helicobacter pylori infection 2020

Contact Info

Product

Resources

About